Market Overview

Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November


SEATTLE, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott D. Myers, President and Chief Executive Officer, will participate in two panel discussions in the month of November.

Scott D. Myers, Cascadian Therapeutics
Scott D. Myers, President and CEO, Cascadian Therapeutics, Inc.

A photo accompanying this announcement is available at

November 7-8, 2017
Boston Biotech Conferences NY/NJ CEO, Apella at Alexandria Center, NY, NY
Panel: State of the Markets: Biotech and Pharma
More information on the conference can be found at

November 13-14, 2017
YJP CEO Europe Forum in Berlin will feature a Healthcare Innovation Symposium
Panel: Transitioning from an R&D Company to a Commercial Venture
More information on YJP and this meeting can be found at

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule kinase inhibitor that is highly selective for HER2 and the Company's lead product in development for the treatment of HER2 overexpressing cancers. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at or For more information, please visit

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics

Primary Logo

View Comments and Join the Discussion!